

PTO/SB/08A (08-03)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 8

Complete if Known

Application Number	10/656,567
Filing Date	September 4, 2003
First Named Inventor	Daug, Edward D.
Art Unit	1614
Examiner Name	To Be Assigned
Attorney Docket Number	016325-008510US


U.S. PATENT DOCUMENTS*

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1	3,378,582	04-16-1968	Bolhofer	
	2	3,444,299	05-13-1969	Wood et al.	
	3	3,469,009	09-23-1969	Klingbail	
	4	3,517,050	06-23-1970	Bolhofer	
	5	3,558,778	01-26-1971	Klingbail	
	6	3,658,829	04-24-1972	Nakamura et al.	
	7	3,674,836	07-04-1972	Creger	
	8	3,860,628	01-14-1975	Shuman	
	9	3,876,791	04-08-1975	Hubbard et al.	
	10	3,923,855	12-02-1975	Shuman	
	11	3,953,490	04-27-1976	Shuman	
	12	4,001,268	01-04-1977	Kovar et al.	
	13	4,067,996	01-10-1978	Najer et al.	
	14	4,146,623	03-1979	Parker	
	15	4,250,191	02-10-1981	Edwards	
	16	4,338,330	07-06-1982	Gillet et al.	
	17	4,508,882	04-02-1985	Yoshida et al.	
	18	4,528,311	07-09-1985	Beard et al.	
	19	4,532,135	07-30-1985	Edwards	
	20	4,714,762	12-22-1987	Hoefle et al.	
	21	4,863,802	09-05-1989	Moore et al.	
	22	4,891,396	01-02-1990	Avar et al.	
	23	4,910,211	03-20-1990	Imamura et al.	
	24	4,933,367	06-12-1990	Wolff et al.	
	25	5,132,429	07-21-1992	Narita et al.	
	26	5,284,599	02-08-1994	Iwaki et al.	
	27	5,476,946	12-19-1995	Linker et al.	
	28	5,496,826	03-05-1996	Watson et al.	
	29	5,500,332	03-19-1996	Vishwakarma et al	
	30	5,516,914	05-14-1996	Winter et al.	
	31	5,554,759	09-10-1996	Vishwakarma	
	32	5,700,819	12-23-1997	Aotsuka et al.	
	33	5,716,987	02-10-1998	Wille	
	34	5,766,834	06-16-1998	Chen et al.	
	35	5,859,051	01-1999	Adams et al.	
	36	5,874,431	02-23-1999	Stevens et al.	
	37	5,883,124	03-1999	Samid	
	38	5,942,626	08-24-1999	Winter et al.	
	39	6,013,659	01-11-2000	Goldfarb et al.	
	40	6,034,246	03-07-2000	Stevens et al.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60127119 v1



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 8**Complete if Known**

Application Number	10/656,567
Filing Date	September 4, 2003
First Named Inventor	Daug, Edward D.
Art Unit	1614
Examiner Name	To Be Assigned
Attorney Docket Number	016325-008510US

U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	41	6,037,493	A	03-14-2000	Mathey et al.	
	42	6,069,272	A	05-30-2000	Crout et al.	
	43	6,093,830	A	07-25-2000	Yadav et al.	
	44	6,184,235		02-06-2001	Connor et al.	
	45	6,201,147	B1	03-13-2001	Bornscheuer et al.	
	46	6,201,000		03-13-2001	Luther et al.	
	47	6,242,464	B1	06-05-2001	Haris et al.	
	48	6,248,768		06-19-2001	Yamada et al.	
	49	6,262,118	B1	07-17-2001	Luskey et al.	
	50	6,506,747	B1	01-14-2003	Betageri et al.	
	51	6,613,802	B1	09-02-2003	Luskey et al.	
	52	6,624,194	B1	09-23-2003	Luskey et al.	
	53	6,646,004	B1	11-11-2003	Luskey et al.	
	54	2003/0220399		11-11-2003	Luskey et al.	
	55	6,670,395		12-30-2003	Wille	
	56	2004/0039053		02-26-2004	Luskey et al.	
	57	2005/0033084		02-10-2005	Daug	
	58	5,716,987		02-10-1998	Wille	
	59	US 2004/0204472		10-14-2004	Briggs	
	60	US 2005/0075396		04-07-2005	Luskey, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	61	FR	1,476,525		04-1967	Merck & Co. Inc.		
	62	GB	1,182,008		02-1970	Roberts, Jr.		
	63	CA	967,978		05-1975	Merck & Co. Inc.		
	64	GB	1,403,309		08-20-1975	Merck & Co. Inc.		
	65	JP	53-15325	A2	02-13-1978	Fujisawa Pharmaceutical Co.		
	66	JP	53-71071	A	06-24-1978	Teijin Ltd.		
	67	EP	0 077 938	A2	05-04-1983	Mitsubishi Chemical Industries, Ltd.		
	68	EP	0 105 494	A2	04-18-1984	Hoechst A.G.		
	69	JP	60-109578	A	06-15-1986	Mitsubishi Chemical Industries, Ltd.		
	70	EP	0 306 708	A1	03-15-1989	Kanebo Ltd.		
	71	WO	92/17435		10-1992	Boehringer Mannheim GmbH		

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.




PTO/SB/08A (08-03)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/656,567
		Filing Date	September 4, 2003
		First Named Inventor	Daugus, Edward D.
		Art Unit	1614
		Examiner Name	To Be Assigned
Sheet 3	of 8	Attorney Docket Number	016325-008510US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	72	WO	98/23252	A1	06-04-1998	Ciba Specialty Chemicals Holding Inc.		
	73	WO	99/11627	A1	03-31-1999	Ortho-McNeil Pharmaceutical, Inc.		
	74	WO	00/35886	A3	06-22-2000	Axys Pharmaceuticals, Inc.		
	75	WO	00/74666	A2	12-14-2000	Metabolex, Inc. et al.		
	76	EP	1 162 196	A1	12-12-2001	Japan Tobacco Inc.		
	77	WO	02/44113	A2	06-06-2002	Metabolex, Inc.		
	78	WO	04/112774	A1	12-29-2004	Metabolex, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60127119 v1



PTO/SB/08B (08-03)

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 8**Complete if Known**

Application Number	10/656,567
Filing Date	September 4, 2003
First Named Inventor	Daug, Edward D.
Art Unit	1614
Examiner Name	
Attorney Docket Number	016325-008510US

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	79	ARONOW, W.S. et al., "Effect of halofenate on serum uric acid," <i>Clin. Pharmacol. Ther.</i> , 1973, Vol. 14, pp 371-373.	
	80	ARONOW, W.S., et al., "Halofenate: An Effective Hypolipemia- and Hypouricemia-Inducing Drug", <i>Current Therapeutic Research</i> , 1973, Vol. 15, No 12, pp 902-906	
	81	BARDIN, C.W., eds., <i>CURRENT THERAPY IN ENDOCRINOLOGY AND METABOLISM</i> , 6th Edition, Mosby - Year Book, Inc., St. Louis, MO, 1997, pp 509-519.	
	82	BARRETT-CONNER, "Epidemiology, Obesity, and Non-Insulin-Dependent Diabetes Mellitus", <i>Epidemiol. Rev.</i> , 1989, Vol. 11, pp 172-181.	
	83	BASSETT, D.R., et al., "Effects of halofenate and probenecid in serum lipids and uric acid in hyperlipidemic, hyperuricemic adults," <i>Clin. Pharmacol. Ther.</i> 1977, Vol. 22, No. 3, pp 340-351.	
	84	BELL, G., et al., "Glucokinase Mutations, Insulin secretion, and Diabetes Mellitus," <i>Annu. Rev. Physiol.</i> , 1996, Vol. 58, No. pp 171-187.	
	85	BERKOW, R., Chapter 94, "Disorders of Carbohydrate Metabolism," <i>The Merck Manual of Diagnosis and Therapy</i> 15th ed., <i>Merck Sharp & Dohme Research Laboratories</i> , 1987, pp 1069-1072.	
	86	BLUESTONE, R., et al., "Halofenate <i>Its Selection and Trial as a Primary Uricosuric Agent</i> ", <i>Arthritis Rheum.</i> , 1975, Vol. 18, pp 859-862.	
	87	BROOKS, D., et al., "Design and Synthesis of 2-Methyl-2-4{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}-propionic Acids: A New Class of Dual PPAR α /y Agonists," <i>J. Med. Chem.</i> , 2001, Vol. 44, pp 2061-2084.	
	88	CHIASSON, J., et al., "The Efficacy of Acarbose in the Treatment of Patients with Non-Insulin-dependant Diabetes Mellitus," <i>Annals of Intern. Med.</i> , 1994 Vol. 121, No. 12, pp 928-935.	
	89	CONIFF, R., et al., "Acarbose: A Review of US Clinical Experience," <i>Clinical Therapeutics</i> , 1997, Vol. 19, No. 1, pp 16-26.	
	90	CONIFF, R., et al., "Multicenter, Placebo-Controlled Trial Comparing Acarbose (BAY g 5421) With Placebo, Tolbutamide, and Tolbutamide-Plus-Acarbose in Non-Insulin-Dependent Diabetes Mellitus," <i>The American Journal of Medicine</i> , 1995, Vol. 98, pp 443-451.	
	91	Diamant, M., et al., "Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence," <i>Drugs</i> , 2003, Vol. 63, pp 1373-1405. ABSTRACT	
	92	DORFLER, H., "Primärer Verteilungsraum und Plasmahalbwertszeit von intravenös verabreichtem Insulin," <i>Med. Poliklinik Univ. München</i> , 1973, pp 1297-1299.	
	93	EDELMAN, S.V., et al., "Non-Insulin-Dependent Diabetes Mellitus", <i>Current Therapy in Endocrinology and Metabolism</i> , 1997, pp 430-438.	
	94	EI-SHERIEF, et al., "Synthesis and Antimicrobial Activities of Some New Benzimidazoles, Part I," <i>Bull. Fac. Sci. Assiut Univ. B</i> , 1995, Vol. 24, No. 1, pp 111-123.	
	95	FAJANS, S., et al., "Maturity Onset Diabetes of the Young (MODY)" <i>Diabetes Medicine</i> , 1996, Vol. 13, pp S90-S95.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

60127119 v1



PTO/SB/08B (08-03)

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 8

Complete if Known

Application Number	10/656,567
Filing Date	September 4, 2003
First Named Inventor	Daug, Edward D.
Art Unit	1614
Examiner Name	
Attorney Docket Number	016325-008510US

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	96	FANELLI, G.M., Jr., "Renal Excretion and Uricosuric Properties of Halofenate A Hypolipidemic Uricosuric Agent in the Chimpanzee," J. Pharmacol. Exp. Ther. 1972, Vol. 180, pp 377-396.	
	97	FELDMAN, E.B., et al., "Effects of Halofenate on Glucose Tolerance in Patients with Hyperlipoproteinemia," Journal Clinical Pharmacology, 1978, Vol. 18, pp 241-248.	
	98	FELDMAN, E.B., et al., "Insulin Sensitivity in Hypertriglyceridemia: induction by combined triglyceride and uric lowering," Clinical Research, 1975, Vol. 23, No. 1, pp 43A.	
	99	FLIER, J., "Insulin Receptors and Insulin Resistance," Ann Rev. Med., 1983, Vol. 34, pp 145-161.	
	100	FRIEDBERG, S.J., "The Control of Insulin Resistant and Refractory Type II Diabetes Mellitus by Means of Halofenate-Sulfonylurea Combined Regimen," Clinical Research, 1986, Vol. 34, pp 682A.	
	101	GAVIN III, J.R., et al., "Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus," Diabetes Care, 1999, Vol. 22, Supplement 1, pp S5-S19.	
	102	GOETZE, S., et al., "PPAR γ -Ligands Inhibit Migration Mediated by Multiple Chemoattractants in Vascular Smooth Muscle Cells," Journal of Cardiovascular Pharmacology, 1999, Vol. 33, pp 798-806.	
	103	HOWARD, B., et al., "Lipoprotein Composition in Diabetes Mellitus," Atherosclerosis, 1978, Volume 30, pp 153-162.	
	104	HUANG, et al., "Search for New Antiphytovirucides," J. Wuhan Univ. (Nature Science Edition), 1995, Vol. 41, No. 2, pp142-148.	
	105	HUCKER, H.B., et al., "Metabolism of a New Hypolipidemic Agent, 2-Acetamidoethyl (p-Chlorophenyl) (m-Trifluoromethylphenoxy)-Acetate (Halofenate) in the Rat, Dog, Rhesus Monkey and Man," The Journal of Pharmacology and Experimental Therapeutics, 1971, Vol. 179, No.2, pp 359-371.	
	106	HUTCHISON, J.C., et al., "The Uricosuric Action of Halofenate (MK-185) in Patients with Hyperuricemia or Uncomplicated Primary Gout and Hyperlipidemia," Atherosclerosis, 1973, Vol. 18, pp 353-362.	
	107	IWAMOTO, Y., et al., "Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Therapy Alone," Diabetic Medicine, 1996, Vol. 13, pp 365-370.	
	108	JACQUES, J., et al., "Formation and separation of diastereomers." in ENANTIOMERS, RACEMATES, AND RESOLUTIONS, pp. 251-328, John Wiley and Sons, New York (1981)	
	109	JAIN, A., et al., "Potentiation of Hypoglycemic Effect of Sulfonylureas by Halofenate," New England J. of Med., 1975, Vol. 293, No. 25, pp 1283-1286.	
	110	JAIN, A., et al., "The effect of MK-185 on some aspects of uric acid metabolism," Clin. Pharmacol. Ther., 1970, Vol. 11, pp 551-557.	
	111	JOSLIN, E., "Arteriosclerosis and Diabetes," Annals of Clinical Medicine, 1927, Vol. 5, no. 12, pp 1061-1079.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

60127119 v1



PTO/SB/08B (08-03)

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 16 of 8**Complete if Known**

Application Number	10/656,567
Filing Date	September 4, 2003
First Named Inventor	Daug, Edward D.
Art Unit	1614
Examiner Name	
Attorney Docket Number	016325-008510US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	112	KELLER C. et al., "Die Benhandlung von Hyperlipidämie und Hyperurikämie mit 2-Acetamidoäthyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetat (Halofenat), einem Derivat des Clofibrat," <i>Arzneimittelforschung</i> , 1976, Vol. 26, No. 12 pp 2221-2224.	
	113	KNOWLER, et al., "Obesity in the Pima Indians: its magnitude and relationship with diabetes," <i>Am. J. Clin. Nutr.</i> , 1991, Vol. 53, pp 1543-1551.	
	114	KOBAYASHI, M., et al., "Improvement of Glucose Tolerance in NIDDM by Clofibrate Randomized Double-Blind Study," <i>Diabetes Care</i> , Vol. 11, No. 6, 1988, pp 495-499.	
	115	KOHL, E. A., et al., "Improved Control of Non-insulin-dependent Diabetes Mellitus by Combined Halofenate and Chlorpropamide Therapy," <i>Diabetes Care</i> , 1984 Vol. 7, No. 1, pp 19-24.	
	116	KREISBERG, R.A., "Hyperlipidemia," <i>Current Therapy in Endocrinology and Metabolism</i> 6th Edition, 1997, pp 509-519.	
	117	KRUT, L. H., et al., "Comparison of Clofibrate with Halofenate in Diabetics with Hyperlipidaemia," <i>S.A. Med. J.</i> , 1977, pp 349-352.	
	118	KUDZMA, D.J., et al., "Potentiation of Hypoglycemic Effect of Chlorpropamide and Phenformin by Halofenate," <i>Diabetes</i> , 1977, Vol. 26, No 4, pp 291-295.	
	119	KUNTZEN Von O. et al., "Wirkung von Halofenat auf Triglycerid-und Harnsäurespiegel sowie auf Gerinnungs- und Thrombozytenverhalten bei Patienten mit Hyperlipoproteinämie Typ IV und Hyperurikämie," <i>Arzneimittelforschung</i> , 1978, Vol. 28, No. 12, pp:2349-2352.	
	120	KWITEROVICH, P., "State-of-the-Art Update and Review: Clinical Trials of Lipid-Lowering Agents," <i>The American Journal of Cardiology</i> , 1998, Vol. 82 No. 12A, pp 3U-17U.	
	121	LEROITH, D. et al. (eds.), <i>Diabetes Mellitus</i> , Lippincott-Raven Publishers, Philadelphia, PA U.S.A. (1996)	
	122	LIN, J.H., et al., "Inhibition and Induction of Cytochrome P450 and the Clinical Implications," <i>Clin Pharmacokinet</i> , 1998, Vol. 35, pp 361-390.	
	123	LISCH, H.J., et al., "Comparison of the Effects of Halofenate (MK-185) and Clofibrate on Plasma Lipid and Uric Acid Concentration in Hyperlipoproteinemic Patients," <i>Atherosclerosis</i> , 1995, Vol. 21, pp 391-399.	
	124	LOCHMÜLLER, et al., "Chromatographic resolution of enantiomers." <i>J. Chromatography</i> 113:283-302 (1975)	
	125	MAHLEY, R. W., et al., "Disorders of Lipid Metabolism, Williams Textbook of Endocrinology, 1998, pp 1099-1153.	
	126	MALHER, R., Clinical Review 102, "Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment," <i>J. Clin. Endocrinol. Metab.</i> , 1999, Vol. 84, No.4, pp 1165-1171.	
	127	MANDEL, Lewis, "Studies on the Mechanism of Action of Halofenate," <i>Lipids</i> , 1976, Vol. 12, No.1., pp. 34-43.	
	128	McMAHON, et al., "Some Effects of MK-185 on Lipid and Uric Acid Metabolism in Man," <i>Univ. Mich. Med. Center J.</i> , 1970, Vol. 36, No. 4, pp 247-248.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

60127119 v1



PTO/SB/08B (08-03)

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 8**Complete if Known**

Application Number	10/656,567
Filing Date	September 4, 2003
First Named Inventor	Daug, Edward D.
Art Unit	1614
Examiner Name	
Attorney Docket Number	016325-008510US

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	129	METABOLEX, The Diabetes Biopharmaceutical Company, "Metabolic Diseases Drug Discovery & Development Summit," Strategic Research Institute, (May 6-7, 2002).	
	130	MINERS, J.O., et al., "Cytochrome P4502C9: an enzyme of major importance in human drug metabolism," J Clin Pharmacol, 1998, Vol. 45, pp 525-538.	
	131	MORGAN, J. P., et al., "Hypolipidemic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate)," Clin. Pharmacol. Therap., 1971, Vol. 12, No. 3, pp 517-524.	
	132	NEUMAN, J., et al., "A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia," The International Cardiovascular Society, pp 532-537.	
	133	PELKONEN, O., et al., "Inhibition and induction of human cytochrome P450 (CYP) enzymes," Xenobiotica, 1998, Vol. 28, No. 12, pp 1203-1253.	
	134	QU, et al., "Search for New Antiphytovirucides," Wujan Univ. Journal of National Science, 1998, Vol. 3 No. 2, pp 201-204.	
	135	QU, et al., "Some New Antiphytoviral Compounds Containing Trifluoromethyl Group," Wuhan Univ. Journal of National Science, 1996, Vol. 1, No. 2, pp 283-284.	
	136	RAVENSROFT, P.J., et al., "Studies of the uricosuric action of the hypolipidemic drug halofenate," Clin. Pharmacol. Ther., 1973, Vol. 14, No. 4, pp 547-551.	
	137	REAVEN, G. M., "Insulin Resistance and Human Disease: A Short History," J. Basic & Clin. Phys. & Pharm., 1998, Vol. 9, No. 2-4, pp 387-406.	
	138	REAVEN, G. M., "Pathophysiology of Insulin Resistance in Human Disease," Physiol. Rev. 1995, Vol. 75, No. 3, pp 473-486.	
	139	RYAN, J. R., "The metabolic spectrum of halofenate," Int. J. Clin. Pharmacol., 1975, Vol. 12, No. 1/2, pp 239-243.	
	140	SAFAK, et al., "Synthesis of Some Benzimidazol Derivatives, and Their Effects on Serum Total Cholesterol and Triglyceride Levels in Rats," FABAD J. Farm. Sci., 1983, Vol. 8, No. 1, pp 19-29.	
	141	SCHAEFFER, S. "Trying to beat PPAR," BioCentury, The Bernstein Report on BioBusiness, (Reprint from June 14, 2004) pp 1-3.	
	142	SCHAPEL, G.J., et al., "Efficacy and Interactions of Oxandrolone, Halofenate and Clofibrate in a Factorial Study on Experimental Acute Nephrotic Hyperlipidemia," The Journal of Pharmacology and Experimental Therapeutics, 1975, Vol. 194, No. 1, pp 274-284.	
	143	SCHLOSSTEIN, L.H., et al. "Studies with some novel uricosuric agents and their metabolites: correlation between clinical activity and drug-induced displacement of urate from its albumin-binding sites," J. Lab. Clin. Med., Vol. 82, No. 3, pp 412-418.	
	144	SIRTORI, C., et al., "Clinical Evaluation of MK-185: A New Hypolipidemic Drug," Lipids, 1971, 7, No. 2, pp 96-99.	
	145	SKYLER, J.S., "Glucose Control in Type 2 Diabetes Mellitus," Annals of Internal Medicine, 1997, Vol. 127, No. 9, pp 837-838.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
60127119 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/656,567		
		Filing Date	September 4, 2003		
		First Named Inventor	Daug, Edward D.		
		Art Unit	1614		
		Examiner Name			
Sheet	8	of	8	Attorney Docket Number	016325-008510US



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	146	STEINER, A., et al., "A Comparative Review of the Adverse Effects of Treatments for Hyperlipidaemia," Drug Safety, 1991, Vol. 6, No. 2, pp 118-130.	
	147	TASKINEN, M.R., "Lipid disorders in NIDDM: implications for treatment," Journal of Internal Medicine, 1998, Vol. 244, pp 361-370.	
	148	TRUST, R. I., et al., "(Aryloxy)[p-(aryloxy)phenyl]- and (Aryloxy)[p-arylthio]phenyl]acetic Acids and Esters as Hypolipidemic Agents," Journal of Medicinal Chemistry, 1979, Vol. 22, No. 9, pp 1068-1074.	
	149	TURNER, N., et al., "Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutic possibilities," Prog Drug Res., 1998, pp 33-94.	
	150	VARMA, et al., "Synthesis of Substituted 2-Phenylbenzothiazoles & 5(6)-Nitro-1, 3-disubstituted-benzimidazoline-2-thiones as CNS Active Agents," Indian Journal of Chemistry, 1988, Vol. 27B, No.5, pp 438-442.	
	151	VEDELL, E.S., et al., "Differential Effects of Chronic Halofenate Administration on Drug Metabolism in Man," Fed. Proc., 1972, Vol. 31, No. 2, pp 538.	
	152	WILSON, J., et al., (ed.) Disorders of Lipid Metabolism, Chapter 23, Textbook of Endocrinology, 9th Edition, 1998, W.B. Sanders Company, Philadelphia, PA. (all references cited therein)	
	153	WOLFRAM, G. et al., "Primärer Verteilungsraum und Plasmahalbwertszeit von intravenös verabreichtem Insulin," Verh. Dtsch. Ges. Inn. Med., 1973, Vol. 79, No. 1, pp 291-1293.	
	154	WRIGHT, A.D., et al., "UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 Diabetes," Diabetes Care, 1998, Vol. 21, pp 87-92.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.